Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
NVDQ's Cash to Debt is ranked higher than
91% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. NVDQ: No Debt )
NVDQ' s 10-Year Cash to Debt Range
Min: 0.72   Max: No Debt
Current: No Debt

Equity to Asset 0.82
NVDQ's Equity to Asset is ranked higher than
90% of the 285 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. NVDQ: 0.82 )
NVDQ' s 10-Year Equity to Asset Range
Min: -0.06   Max: 0.96
Current: 0.82

-0.06
0.96
Interest Coverage No Debt
NVDQ's Interest Coverage is ranked higher than
83% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 261.43 vs. NVDQ: No Debt )
NVDQ' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 13.39
M-Score: 0.41
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -49.15
NVDQ's Operating margin (%) is ranked higher than
59% of the 290 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.79 vs. NVDQ: -49.15 )
NVDQ' s 10-Year Operating margin (%) Range
Min: -1278.97   Max: -13.33
Current: -49.15

-1278.97
-13.33
Net-margin (%) -53.96
NVDQ's Net-margin (%) is ranked higher than
59% of the 290 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.93 vs. NVDQ: -53.96 )
NVDQ' s 10-Year Net-margin (%) Range
Min: -1103.37   Max: -52.26
Current: -53.96

-1103.37
-52.26
ROE (%) -14.93
NVDQ's ROE (%) is ranked higher than
64% of the 273 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.49 vs. NVDQ: -14.93 )
NVDQ' s 10-Year ROE (%) Range
Min: -522.79   Max: -15.03
Current: -14.93

-522.79
-15.03
ROA (%) -12.29
NVDQ's ROA (%) is ranked higher than
64% of the 299 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.00 vs. NVDQ: -12.29 )
NVDQ' s 10-Year ROA (%) Range
Min: -95.21   Max: -12.38
Current: -12.29

-95.21
-12.38
ROC (Joel Greenblatt) (%) -95.18
NVDQ's ROC (Joel Greenblatt) (%) is ranked higher than
62% of the 298 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.09 vs. NVDQ: -95.18 )
NVDQ' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3434.48   Max: -33.03
Current: -95.18

-3434.48
-33.03
Revenue Growth (3Y)(%) 24.70
NVDQ's Revenue Growth (3Y)(%) is ranked higher than
96% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.20 vs. NVDQ: 24.70 )
NVDQ' s 10-Year Revenue Growth (3Y)(%) Range
Min: -6.9   Max: 149.3
Current: 24.7

-6.9
149.3
EBITDA Growth (3Y)(%) 17.60
NVDQ's EBITDA Growth (3Y)(%) is ranked higher than
89% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.90 vs. NVDQ: 17.60 )
NVDQ' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -30.7   Max: 67.7
Current: 17.6

-30.7
67.7
EPS Growth (3Y)(%) 15.70
NVDQ's EPS Growth (3Y)(%) is ranked higher than
90% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.20 vs. NVDQ: 15.70 )
NVDQ' s 10-Year EPS Growth (3Y)(%) Range
Min: -26.9   Max: 64.2
Current: 15.7

-26.9
64.2
» NVDQ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

NVDQ Guru Trades in Q1 2014

Ron Baron 19,280 sh (+44.64%)
Chuck Royce 120,000 sh (-11.11%)
» More
Q2 2014

NVDQ Guru Trades in Q2 2014

Chuck Royce 60,000 sh (-50.00%)
Ron Baron 4,680 sh (-75.73%)
» More
Q3 2014

NVDQ Guru Trades in Q3 2014

Steven Cohen 130,400 sh (New)
Ron Baron 47,400 sh (+912.82%)
Chuck Royce 60,000 sh (unchged)
» More
Q4 2014

NVDQ Guru Trades in Q4 2014

PRIMECAP Management 760,082 sh (New)
Chuck Royce 77,700 sh (+29.50%)
Ron Baron 57,600 sh (+21.52%)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NVDQ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 121.95
NVDQ's Forward P/E is ranked higher than
80% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NVDQ: 121.95 )
N/A
P/B 4.50
NVDQ's P/B is ranked higher than
57% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. NVDQ: 4.50 )
NVDQ' s 10-Year P/B Range
Min: 0.91   Max: 274
Current: 4.5

0.91
274
P/S 14.10
NVDQ's P/S is ranked lower than
55% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.98 vs. NVDQ: 14.10 )
NVDQ' s 10-Year P/S Range
Min: 1.67   Max: 327.33
Current: 14.1

1.67
327.33
Current Ratio 22.86
NVDQ's Current Ratio is ranked higher than
99% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.52 vs. NVDQ: 22.86 )
NVDQ' s 10-Year Current Ratio Range
Min: 1   Max: 22.86
Current: 22.86

1
22.86
Quick Ratio 21.91
NVDQ's Quick Ratio is ranked higher than
99% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. NVDQ: 21.91 )
NVDQ' s 10-Year Quick Ratio Range
Min: 0.85   Max: 21.91
Current: 21.91

0.85
21.91
Days Inventory 114.39
NVDQ's Days Inventory is ranked higher than
73% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 139.33 vs. NVDQ: 114.39 )
NVDQ' s 10-Year Days Inventory Range
Min: 53.18   Max: 310.42
Current: 114.39

53.18
310.42
Days Sales Outstanding 116.29
NVDQ's Days Sales Outstanding is ranked higher than
61% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.03 vs. NVDQ: 116.29 )
NVDQ' s 10-Year Days Sales Outstanding Range
Min: 37.76   Max: 344.72
Current: 116.29

37.76
344.72

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.60
NVDQ's Price/Net Cash is ranked higher than
93% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NVDQ: 6.60 )
NVDQ' s 10-Year Price/Net Cash Range
Min: 6.14   Max: 29.3
Current: 6.6

6.14
29.3
Price/Net Current Asset Value 5.80
NVDQ's Price/Net Current Asset Value is ranked higher than
90% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NVDQ: 5.80 )
NVDQ' s 10-Year Price/Net Current Asset Value Range
Min: 4.31   Max: 19.11
Current: 5.8

4.31
19.11
Price/Tangible Book 4.90
NVDQ's Price/Tangible Book is ranked higher than
76% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. NVDQ: 4.90 )
NVDQ' s 10-Year Price/Tangible Book Range
Min: 2.6   Max: 455
Current: 4.9

2.6
455
Price/Median PS Value 1.10
NVDQ's Price/Median PS Value is ranked higher than
76% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. NVDQ: 1.10 )
NVDQ' s 10-Year Price/Median PS Value Range
Min: 0.15   Max: 23.17
Current: 1.1

0.15
23.17
Earnings Yield (Greenblatt) -3.50
NVDQ's Earnings Yield (Greenblatt) is ranked higher than
61% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.30 vs. NVDQ: -3.50 )
NVDQ' s 10-Year Earnings Yield (Greenblatt) Range
Min: -3.6   Max: 0
Current: -3.5

-3.6
0

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:NDQ.Canada, NQT.Germany,
Novadaq Technologies Inc was incorporated under the Canada Business Corporations Act on April 14, 2000. The Company develops and commercializes medical imaging and therapeutic devices for use in the operating room. It's imaging platform can be used to visualize blood vessels, nerves and the lymphatic system during surgical procedures. The Company's business activities are conducted through one segment, which consists of medical devices. Its product includes, SPY Elite, PINPOINT Endoscopic Fluorescence Imaging, FIREFLY System for Robotic Surgery, LUNA Fluorescence Angiography and CO2 HEART LASER System. The SPY Imaging System provides clinically relevant information that empowers surgeons to make informed critical decisions in the operating room. PINPOINT Endoscopic Fluorescence Imaging System combines all of the fluorescence imaging capabilities of SPY Imaging with the HD visible light imaging capabilities of a traditional endoscopic imaging system. FIREFLY system enables surgeons performing robotic surgery to benefit from fluorescence imaging, with initial use in applications ranging from urology to gynecology. LUNA fluorescence angiography enables clinicians to visually assess tissue perfusion in diabetic foot ulcers and non-healing wounds. The CO2 HEART LASER System consists of: the CO2 HEART LASER mobile console and the CO2 HEART LASER disposable hand pieces. The Company's intellectual property consists of 49 patent families representing 128 granted or allowed patents and 90 pending applications in various stages of review and prosecution.
» More Articles for NVDQ

Headlines

Articles On GuruFocus.com
Prem Watsa Increases NYT and Two Others May 15 2013 
comment on NVDQ Mar 03 2013 
Prem Watsa Increases Novadaq Technologies Ownership to 6.6 Pct Feb 14 2013 

More From Other Websites
Nasdaq stocks posting largest percentage decreases Apr 24 2015
Nasdaq stocks posting largest percentage decreases Apr 24 2015
NOVADAQ to Release First Quarter 2015 Financial Results on April 28, 2015 – Conference Call to... Apr 15 2015
NOVADAQ to Release First Quarter 2015 Financial Results on April 28, 2015 -- Conference Call to... Apr 15 2015
NOVADAQ TECHNOLOGIES INC Financials Mar 31 2015
NOVADAQ To Participate in Upcoming Investor Conferences Mar 23 2015
NOVADAQ to Participate in Upcoming Investor Conferences Mar 23 2015
NOVADAQ Announces Appointment of Patrice E. Merrin to Its Board of Directors Mar 12 2015
NOVADAQ to Present at the 2015 Barclays Global Healthcare Conference Mar 09 2015
NOVADAQ Announces Appointment of Patrice E. Merrin to Its Board of Directors Mar 09 2015
NOVADAQ to Present at the 2015 Barclays Global Healthcare Conference Mar 04 2015
5 Health Care Stocks to Trade for Breakout Gains in March Mar 03 2015
NOVADAQ Reports Fourth Quarter and Full Year 2014 Financial Results Mar 03 2015
Novadaq reports 4Q loss Feb 25 2015
Novadaq reports 4Q loss Feb 25 2015
NOVADAQ Reports Fourth Quarter and Full Year 2014 Financial Results Feb 25 2015
NOVADAQ to Host Fourth Quarter and Fiscal Year 2014 Earnings Conference Call and Webcast Live on... Feb 24 2015
NOVADAQ to Release Fourth Quarter and Full Year 2014 Financial Results on February 25, 2015 --... Feb 10 2015
NOVADAQ to Participate in February Investor Conferences Feb 10 2015
NOVADAQ Announces Fourth Quarter 2014 Preliminary Unaudited Revenues and Issues 2015 Revenue... Jan 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK